Condition
Hemorrhagic Fever
Total Trials
6
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 2 (1)
P 3 (1)
Trial Status
Completed4
Not Yet Recruiting1
Suspended1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT04283513Phase 2SuspendedPrimary
Treatment of Hemorrhagic Fever With Ribavirin
NCT07591740CompletedPrimary
Xpert Hemorrhagic Fever on Edge X in Trained and Untrained Users
NCT07543458Phase 3Not Yet Recruiting
Therapeutics for Moderate and Severe Dengue
NCT07370454CompletedPrimary
Xpert® Hemorrhagic Fever on the GeneXpert® Edge X System
NCT02368119Phase 1Completed
Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO)
NCT02267109Phase 1Completed
Phase 1 Trial of Ebola Vaccine in Mali
Showing all 6 trials